Former $IXHL holder—what’s the current sentiment on Incannex Healthcare?

Former $IXHL holder—what’s the current sentiment on Incannex Healthcare? Used to hold $IXHL about a year ago and ended up selling out. Not looking to jump back in anytime soon, but I was checking in on it recently and was curious what the consensus is on Incannex right now? Looks like their lead candidate for Sleep Apnea (IHL-42X) got FDA Fast Track status, and they recently began dosing patients in their Phase 2 DReAMzz trial. Plus they’ve got a psilocybin program for anxiety (PSX-001). Financially, they reported \~$70M in cash with runway into 2027, though they've had some dilution and a reverse split earlier.  For anyone still holding or tracking it—what’s your take on their pipeline and chances of bringing a product to market? Worth keeping on a watchlist, or standard micro-cap bio trap?